<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9955">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686733</url>
  </required_header>
  <id_info>
    <org_study_id>TP0025</org_study_id>
    <nct_id>NCT05686733</nct_id>
  </id_info>
  <brief_title>Pre SEAL™ IT: Saccular Endovascular Aneurysm Lattice System First In Human Interventional Trial</brief_title>
  <acronym>Pre SEAL™ IT</acronym>
  <official_title>Pre SEAL™ IT: Saccular Endovascular Aneurysm Lattice System First In Human Interventional Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galaxy Therapeutics INC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galaxy Therapeutics INC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the preliminary safety and effectiveness of the SEAL™ Endovascular Aneurysm&#xD;
      Lattice System for the treatment of saccular intracranial aneurysms.&#xD;
&#xD;
      The data from this study will be used to support:&#xD;
&#xD;
        1. EU CE Mark labelling&#xD;
&#xD;
        2. US FDA Investigational Device Exemption (IDE) approval support of PMA approval.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First In Human (FIH), prospective, single-arm, multicenter, interventional study. Patients&#xD;
      presenting with evidence of a single unruptured or ruptured aneurysm requiring treatment will&#xD;
      be enrolled into the study and treated using the SEAL™ System.&#xD;
&#xD;
      Immediate post-procedure angiographic findings, clinical presentation, safety, and imaging&#xD;
      follow-up for each subject will be collected at 24 hours, 3 (MRA), 6, 12 and 24-months&#xD;
      post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>First In Human (FIH), prospective, single-arm, multicenter, interventional study. Patients presenting with evidence of a single unruptured or ruptured aneurysm requiring treatment will be enrolled into the study and treated using the SEAL™ System.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>Procedure through 12 Months</time_frame>
    <description>Subject Safety will be considered a failure upon meeting any of the following primary safety criteria:&#xD;
Any stroke within 72 hours of the procedure or discharge home (if earlier) that results in an increase of 4 or more points on the National Institute of Health Stroke Scale&#xD;
Major ipsilateral stroke within 72 hours post-procedure or discharge home (if earlier) to 12-months following treatment&#xD;
New subarachnoid hemorrhage related to target aneurysm within 72 hours post-procedure or discharge home (if earlier) to 12-months following treatment&#xD;
Death due to neurologic cause related to aneurysm treated from Procedure to 12-months following treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>Procedure through 12 Months</time_frame>
    <description>Proportion of subjects with aneurysm occlusion adjudicated by independent core lab based on satisfaction of the following 3 criterion:&#xD;
WEB-IT Occlusion Scale I and II (WOS) post-implantation, at 6 months, and at 12 months&#xD;
Raymond Roy Scale I (RRS) post-implantation, at 6 months, and at 12 months&#xD;
Technical success defined as the proportion of subjects in whom a SEAL™ System was successfully delivered and deployed at the target aneurysm</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aneurysms Saccular</condition>
  <condition>Aneurysm, Ruptured</condition>
  <condition>Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SEAL Device</intervention_name>
    <description>Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 to 80 years of age at the time of screening&#xD;
&#xD;
          2. Evidence of a single unruptured aneurysm requiring treatment. If there is evidence of&#xD;
             an additional aneurysm requiring treatment, the secondary aneurysm must also be&#xD;
             treatable using a SEAL™ System Device, either during a single procedure or consecutive&#xD;
             procedures.&#xD;
&#xD;
             In these instances, no additional implanted devices are permissible except for as&#xD;
             medically required for patient safety.&#xD;
&#xD;
               1. Ruptured aneurysms may be included according the following criteria: The subject&#xD;
                  is neurologically stable with a Hunt and Hess scale of 3 or less at the time of&#xD;
                  treatment&#xD;
&#xD;
               2. Modified Disability Scale (mRS) of ≤2 prior to presentation or rupture&#xD;
&#xD;
          3. The index intracranial aneurysm (IA) to be treated must include the following&#xD;
             features:&#xD;
&#xD;
               1. Aneurysm features suitable for endovascular treatment with an intrasaccular&#xD;
                  device per the treating interventionist.&#xD;
&#xD;
               2. Saccular morphology&#xD;
&#xD;
               3. Located at a bifurcation, terminus, or sidewall in the anterior or posterior&#xD;
                  circulation&#xD;
&#xD;
               4. 3mm-25mm in dome diameter&#xD;
&#xD;
               5. Narrow or wide-neck aneurysm with neck size ≥ 4mm or Dome-to-Neck (DN) ratio &lt; 2&#xD;
&#xD;
          4. Aneurysm treatment does not require the preplanned use of any additional implanted&#xD;
             devices&#xD;
&#xD;
          5. Subject is able to maintain compliance with all aspects of screening, evaluation,&#xD;
             treatment, and post-procedure follow-up schedule&#xD;
&#xD;
          6. Baseline mRS of 0-1 for unruptured cases&#xD;
&#xD;
          7. Ability to obtain written informed consent from subject prior to the initiation of any&#xD;
             study procedures&#xD;
&#xD;
          8. Subject has been approved for inclusion by Galaxy Therapeutics INC. clinical affairs&#xD;
             team.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Aneurysm features unsuitable for endovascular treatment with an intrasaccular device&#xD;
             such as fusiform, dissecting pseudo aneurysm, or mycotic aneurysm.&#xD;
&#xD;
          2. Aneurysms smaller than 3mm and larger than 25mm in dome diameter.&#xD;
&#xD;
          3. Inability to access target aneurysm with microcatheter due to intracranial&#xD;
             atherosclerosis, vessel tortuosity or poor aneurysm angle take-off.&#xD;
&#xD;
          4. Presence of vascular disease or other vascular abnormality that could prohibit access&#xD;
             to index aneurysm such carotid stenosis or diminished caliber of the target artery.&#xD;
&#xD;
          5. Proximal vessel tortuosity or morphology that could prohibit access to target aneurysm&#xD;
&#xD;
          6. Clinical, angiographic, or CT evidence of CNS arterial vasculitis, moyamoya disease,&#xD;
             intracranial tumor (except small meningioma), or any other intracranial vascular&#xD;
             malformations&#xD;
&#xD;
          7. Patients with high risk for recurrent ischemic stroke due to previous history of&#xD;
             intracranial ischemic stroke symptoms such as transient ischemic attacks (TIAs),&#xD;
             minor, or major strokes within the past 60 days&#xD;
&#xD;
          8. Patients with hemodynamic or medical compromise due to medical comorbidities such as&#xD;
             severe unstable congestive heart failure (ejection fraction &lt;30%) or severe COPD&#xD;
             requiring home oxygen.&#xD;
&#xD;
          9. Modified Rankin Scale (mRS) score of ≤ 2 prior to presentation or acute rupture (as&#xD;
             applicable)&#xD;
&#xD;
         10. SAH from non-index aneurysm or any other intracranial hemorrhage within the past 60&#xD;
             days&#xD;
&#xD;
         11. Target aneurysm has been previously treated and contains devices, implants, or coils&#xD;
             that could interfere with correct SEAL™ device placement.&#xD;
&#xD;
         12. Subject is pregnant or a lactating female (For females of child-bearing potential, a&#xD;
             positive pregnancy test within 7 days of the day of procedure or refusal to use a&#xD;
             medically accepted method of birth control for the duration of the study.&#xD;
&#xD;
         13. Currently on anticoagulation therapy or has a known blood dyscrasia, coagulopathy, or&#xD;
             hemoglobinopathy&#xD;
&#xD;
         14. Hypersensitivity that cannot be medically controlled to any component of the SEAL™&#xD;
             System, procedural materials, or medications commonly used during the procedure&#xD;
&#xD;
         15. Currently enrolled in another investigational study or post-market study that could&#xD;
             affect the safety and efficacy of aneurysm treatment or interfere with the study&#xD;
             follow- up schedule&#xD;
&#xD;
         16. Presence of an acute life-threatening illness requiring treatment&#xD;
&#xD;
         17. Life-expectancy of &lt; 5 years&#xD;
&#xD;
         18. Subject has an uncontrolled co-morbid medical condition, including mental health&#xD;
             issues, that would adversely affect participation in the study&#xD;
&#xD;
         19. Subject is a prisoner or member of other vulnerable population&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary S Patterson</last_name>
    <phone>16143571718</phone>
    <email>mary@galaxytherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Osama O Zaidat, MD, MS</last_name>
    <email>szaidat@galaxytherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinicas Las Americas</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris L Pabon Guerrero, MD</last_name>
      <email>borispabon@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 30, 2022</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>January 9, 2023</last_update_submitted>
  <last_update_submitted_qc>January 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aneurysm, Ruptured</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

